MINI FUTURE SHORT - NOVO-NORDISK B | Market Closed - Euronext Paris 11:02:50 2024-07-03 EDT | ||
| 2.46 EUR | +23.62% |
|
| Current month | +34.43% | ||
| 1 month | -15.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 2.46 | +23.62% |
| 24-07-02 | 1.99 | +13.71% |
| 24-07-01 | 1.75 | -4.37% |
| 24-06-28 | 1.83 | -3.17% |
| 24-06-27 | 1.89 | +3.85% |
Real-time Euronext Paris
Last update July 03, 2024 at 11:02 am
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| QI4NB | |
| ISIN | NLBNPNL2NS92 |
| Date issued | 2024-02-19 |
| Strike | 1,142 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.98 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.435 € |
|---|---|
| Lowest since issue | 1.49 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Certificates
- QI4NB Certificat
